AMO Pharma (United Kingdom)

Can Target Costing and Whole Life Costing be Applied in the Construction Industry?: Evidence from Two Case Studies

Davide Nicolini, Cyril Tomkins, Richard Holti et al. · British Journal of Management · 2000 · 158 citations

Management, Construction Management, Supply Chain Management +14

A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome

Elizabeth Berry‐Kravis, Joseph P. Horrigan, Nicole Tartaglia et al. · Pediatric Neurology · 2020 · 104 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)

Joseph P. Horrigan, Tiago Gomes, Mike Snape et al. · Pediatric Neurology · 2020 · 89 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +9

The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder

Paul Herscu, Benjamin L. Handen, L. Eugene Arnold et al. · Journal of Autism and Developmental Disorders · 2019 · 62 citations

Medicine, Pharmacotherapy, Psychiatry +17

Correction of Glycogen Synthase Kinase 3 <i>β</i> in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice

Mei Wang, Wen‐Chin Weng, Lauren Stock et al. · Molecular and Cellular Biology · 2019 · 44 citations · Full text

Medicine, Molecular Genetics, Molecular Medicine +11